Viracta Therapeutics Inc expected to post a loss of 30  cents a share - Earnings Preview

Viracta Therapeutics

08/08/2022 18:22

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Viracta
Therapeutics Inc
is for a loss of 30 cents per share. For the same quarter last
year, the company reported a loss of 25 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $15​, above​ its last closing price
of $3.87. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    11.1
 Dec. 31 2022  -0.43       -0.43      -0.31     Beat    28.7
 Sep. 30 2021  -0.30       -0.31      -0.40     Missed  -29​
 Jun. 30 2021  -0.24       -0.24      -0.25     Missed  -5.6
 ​​Mar.        0.03        -0.21      0.35      Beat    266.7
 31 2021                                                
 Dec. 31 2020  -0.96       -0.96      -0.73     Beat    23.6​
 Sep. 30 2020  -1.21       -1.18      -1.01     Beat    13.9
 Jun. 30 2020  -1.87       -1.94      -2.10     Missed  -8.1
 This summary was machine generated August 8 at 17:22 GMT.  All
figures in US dollars  unless otherwise stated